Ocular oncologist Miguel Materin, MD joined Duke Eye Center as Professor of Ophthalmology and Director of Ophthalmic Oncology in September 2016. He joins Duke from Yale University School of Medicine where he was an Associate Professor of Ophthalmology & Visual Science. Prior to his appointment at Yale, he was at Wills Eye Hospital at Thomas Jefferson University in Philadelphia, where he served as Director of Diagnostic Studies for the Ocular Oncology Service.
Dr. Materin’s clinical practice involves diagnosis and treatment of patients with ocular tumors, including benign and malignant tumors of the eye. He has special interests in ocular melanoma, retinoblastoma, choroidal hemangiomas, retinal hemangioblastomas, metastases, astrocytic tumors and tumors related to other conditions or syndromes, like von Hippel Lindau disease, Tuberous Sclerosis among others.
He is an internationally recognized ocular oncologist, who has served as a member of the International Advisory Board (Ocular Oncology) for the Canadian Journal of Ophthalmology. Dr. Materin has published extensively in the peer-reviewed literature, including journals and book chapters. He has been invited as visiting professor in US, Canada, Israel, Spain, Brazil, Puerto Rico, Argentina, and gave lectures worldwide.
Dr. Materin has received the Achievement Award from the American Academy of Ophthalmology and he is a Member of Merit of Clinica Barraquer (Barcelona, Spain). He has served as Director of Diagnostic Studies at the Ocular Oncology Service at Wills Eye Hospital for 7 years. He is an active member of the International Society of Ocular Oncology, American Academy of Ophthalmology, Pan American Association of Ophthalmology and Argentine Society of Ophthalmology.
Dr. Materin serves on the education committee of the American Association of Ocular Oncology and Pathology and is the President Elect for the Pan American Society of Ocular Oncology.